The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections – a randomized, double-blinded, placebo-controlled clinical trial study protocol

BACKGROUND: Uncomplicated lower urinary tract infections (LUTI) are very common, and presumably around 200,000 female patients are treated for this annually in Denmark. The current Danish national clinical practice guidelines recommend pivmecillinam as a first-line drug (i.e., 400 mg t.i.d. for 3 da...

Descripción completa

Detalles Bibliográficos
Autores principales: Jansåker, Filip, Frimodt-Møller, Niels, Bjerrum, Lars, Dahl Knudsen, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134065/
https://www.ncbi.nlm.nih.gov/pubmed/27905884
http://dx.doi.org/10.1186/s12879-016-2022-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134065/
https://www.ncbi.nlm.nih.gov/pubmed/27905884
http://dx.doi.org/10.1186/s12879-016-2022-0

Ejemplares similares